Skip to content

SHMT1 Polymorphism in Parkinson's Disease,

Genetic Polymorphisms of Serine Hydroxylmethyl Transferase 1 (SHMT1) in Patients With Parkinson's Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04706065
Enrollment
80
Registered
2021-01-12
Start date
2021-01-31
Completion date
2022-01-31
Last updated
2021-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Study the Role of SHMT1 Polymorphism in Parkinson Disease

Keywords

SHMT1 polymorphism, Parkinson disease

Brief summary

Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.

Detailed description

This case -control observational prospective study will conducted on 40 patients with PD.

Interventions

GENETICSHMT1 polymorphism

It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.

Sponsors

Aswan University Hospital
CollaboratorOTHER
Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients age ≥ 50 years. * Patients with PD diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank (UK PDS Brain Bank diagnostic criteria)

Exclusion criteria

* Patients with parkinsonian plus syndrome * Patients with secondary parkinsonism * Patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.) * Past and /or present history of epilepsy. * Patients with disturbed conscious level.

Design outcomes

Primary

MeasureTime frame
polymorphism of SHMT1geneone year

Secondary

MeasureTime frame
the role of SHMT1plymorphism in pathogenesis PDone year
Study the relationship of Shmt1 polymorphism to the severity of Parkinson diseaseOne year

Countries

Egypt

Contacts

Primary ContactEffat a Tony, MD
effattony@aun.edu.eg+201097330309
Backup Contactabeer a tony, MD
abeer.tony@aswu.edu.eg+201005389084

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026